Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia

2012 ◽  
Vol 12 (5) ◽  
pp. 492-501 ◽  
Author(s):  
D. Aarsland ◽  
C. Ballard ◽  
A. Rongve ◽  
M. Broadstock ◽  
P. Svenningsson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Parkinson’S Disease Dementia

A-21 Neuropsychological Differentiation of Dementia with Lewy Bodies and Parkinson’s Disease Dementia

2021 ◽  
Vol 36 (6) ◽  
pp. 1062-1062
Author(s):  
Bailey E McDonald ◽  
Samantha Spagna ◽  
Charles Golden
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Executive Functioning ◽  
Dementia With Lewy Bodies ◽  
Financial Burden ◽  
Digit Span ◽  
Neuropsychological Testing ◽  
Lewy Bodies ◽  
Parkinson’S Disease Dementia ◽  
Figure Test

Abstract Objective To determine whether or not distinct neuropsychological profiles could be created to aid in earlier detection in Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD). Data Selection A literature review was conducted informally to search for articles pertaining to neuropsychological testing with individuals with DLB or PDD that were dated within the past fifteen years. Data Synthesis Results indicated DLB typically has greater impairment in executive functioning, visuospatial, and attention in comparison to PDD. More specifically, individuals with DLB had significantly worse results on the Rey Complex Figure Test Copy Trial and Digit Span Forward than individuals with PDD. PDD was shown to typically have greater impairment in motor symptoms in comparison to DLB. These impairments, however, depend on the severity of disease progression. Conclusions In conclusion, DLB and PDD have very similar neuropsychological deficits, with greater deficits observed in executive functioning, visuospatial, and attention for individuals with DLB. Overall, majority of the literature is unsure of concrete diagnostic criteria for both individuals with DLB and PDD. This inconsistency has led the comparison of overall research to also been quite difficult as well. Future studies should try to control for medication and comorbidities, as well as include larger and more diverse samples with a full neuropsychological battery to include all domains of functioning. By doing this, the focus will shift more to on early detection and prevention of DLB and PDD and therefore reduce the financial burden of a neurocognitive disorder and the strain of caregiving that is usually placed within on the family.

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia

2010 ◽  
Vol 25 (10) ◽  
pp. 1030-1038 ◽  
Author(s):  
Victoria Larsson ◽  
Dag Aarsland ◽  
Clive Ballard ◽  
Lennart Minthon ◽  
Elisabet Londos
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Parkinson’S Disease Dementia ◽  
Sleep Behaviour

scholarly journals Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies

Brain ◽  
2005 ◽  
Vol 128 (6) ◽  
pp. 1267-1276 ◽  
Author(s):  
Urs P. Mosimann ◽  
René M. Müri ◽  
David J. Burn ◽  
Jacques Felblinger ◽  
John T. O'Brien ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Eye Movement ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Saccadic Eye Movement ◽  
Parkinson’S Disease Dementia

Dementia with Lewy bodies and Parkinson’s disease dementia

2013 ◽  
Author(s):  
Arvid Rongve ◽  
Dag Aarsland
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dementia With Lewy Bodies ◽  
Clinical Symptoms ◽  
Imaging Techniques ◽  
Lewy Bodies ◽  
Epidemiological Data ◽  
Parkinson’S Disease Dementia ◽  
Esterase Inhibitors ◽  
Staging Systems

Dementia with Lewy bodies and Parkinson’s disease dementia belong to the α-synucleinopathies, a family of diseases pathologically characterized by aggregation of α-synuclein in Lewy bodies in the brain. In this chapter we present the epidemiological data for both conditions including new data on MCI. Clinical diagnostic criteria are reviewed and the different neuropathology staging systems for DLB and PDD and the most important genetic findings are considered. Biomarkers in DLB and PDD with particular focus on imaging techniques like CIT-SPECT and MRI are described. Important clinical symptoms in both conditions are presented in detail and the most important clinical differential diagnoses are discussed. Pharmacological and non- pharmacological treatment of different symptoms in both conditions are discussed with particular emphasis on the choline esterase inhibitors and antipsychotic medications.New data on memantine are presented.

Sign in / Sign up

Export Citation Format

Share Document